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Many bioactive natural products are glycosylated compounds in which the sugar
components usually participate in interaction and molecular recognition of the cellular
target. Therefore, the presence of sugar moieties is important, in some cases essential,
for bioactivity. Searching for novel glycosylated bioactive compounds is an important
aim in the field of the research for natural products from actinomycetes. A great
majority of these sugar moieties belong to the 6-deoxyhexoses and share two common
biosynthetic steps catalyzed by a NDP-D-glucose synthase (GS) and a NDP-D-glucose
4,6-dehydratase (DH). Based on this fact, seventy one Streptomyces strains isolated
from the integument of ants of the Tribe Attini were screened for the presence of
biosynthetic gene clusters (BGCs) for glycosylated compounds. Total DNAs were
analyzed by PCR amplification using oligo primers for GSs and DHs and also for a NDP-
D-glucose-2,3-dehydratases. Amplicons were used in gene disruption experiments to
generate non-producing mutants in the corresponding clusters. Eleven mutants were
obtained and comparative dereplication analyses between the wild type strains and
the corresponding mutants allowed in some cases the identification of the compound
coded by the corresponding cluster (lobophorins, vicenistatin, chromomycins and
benzanthrins) and that of two novel macrolactams (sipanmycin A and B). Several strains
did not show UPLC differential peaks between the wild type strain and mutant profiles.
However, after genome sequencing of these strains, the activation of the expression
of two clusters was achieved by using nutritional and genetic approaches leading to
the identification of compounds of the cervimycins family and two novel members
of the warkmycins family. Our work defines a useful strategy for the identification
new glycosylated compounds by a combination of genome mining, gene inactivation
experiments and the activation of silent biosynthetic clusters in Streptomyces strains.
Keywords: polyketides, Streptomyces, deoxy sugars, glycosylation, genome mining
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INTRODUCTION
Natural products are an important source of clinical and
pharmaceutical compounds and they also contribute with
compounds showing agricultural and veterinary applications.
A large proportion of natural products are synthesized by
microorganisms which constitute a prolific source of structurally
diverse bioactive metabolites and have yielded some of the
most important products of the pharmaceutical industry.
Within microorganisms, the actinomycete family constitutes
a good reservoir of natural products: approximately two-
thirds of all natural products are produced by members of
this family (Bérdy, 2005; Demain and Sanchez, 2009). Most
of the natural products identified have emerged from large
screening programs carried out by pharmaceutical companies.
However, in the last years, the interest in the search for
natural products has in some way declined. One of the
reasons is the redundancy in the discovery of natural products
with many of the newly isolated compounds corresponding
to already known compounds. However, the growing rate of
multi-resistant pathogens, the appearance of new ones and
the need for more effective chemotherapeutic agents, together
with the development of DNA sequencing technologies, are
facilitating a return to the search for bioactive natural products
from actinomycetes (Newman and Cragg, 2016; Zhang et al.,
2017a). From the sequencing of the first complete genome of
actinomycetes, up to date more than 1,000 genomes have been
sequenced and annotated (Gomez-Escribano et al., 2016). With
the bioinformatic analyses of these genomes became evident
that actinomycetes carry the genetic potential to produce many
more natural products than those detected under laboratory
conditions. It is frequent to observe that the sequenced genomes
of actinomycetes contain between 20 and 30 biosynthetic gene
clusters (BGCs) for secondary metabolites production. Many
of these BGCs are not expressed (or are very low expressed)
under laboratory cultivation conditions and are designated as
“silent” clusters. Several strategies have been applied to awake
these clusters including nutritional (Bode et al., 2002) and
genetic approaches (Challis, 2008; Laureti et al., 2011; Olano
et al., 2014; Thanapipatsiri et al., 2016; Zhang et al., 2017b)
and ribosomal engineering (Ochi et al., 2004; Ochi and Hosaka,
2013).
Many BGCs code for glycosylated metabolites (Weymouth-
Wilson, 1997). Therapeutically important antibiotics
(erythromycin), antifungals (amphotericin B), antiparasitics
(avermectins) and anticancer drugs (doxorubicin) contain
sugars attached to the aglycone core. They contribute to create
structural biodiversity in natural products and they participate
in the interaction between the drug and the cellular target.
Consequently, their presence is important, in many cases
essential, for the biological activity of many bioactive natural
products (Méndez and Salas, 2001; Salas and Méndez, 2005).
Most of these sugars are 6-deoxyhexoses (6DOH), of which more
than 70 different forms have been identified (Thorson et al., 2001;
Méndez et al., 2008; Thibodeaux et al., 2008). Its biosynthesis
shares the first two steps where D-glucose-1-phosphate is
converted into NDP-D-glucose by a NDP-D-glucose synthase
(GS) and then dehydrated by a NDP-D-glucose-4,6-dehydratase
(DH). Afterwards, the common intermediate NDP-4-keto-6-
deoxy-D-glucose is subjected to several modification reactions,
including deoxygenations (frequently by a 2,3-dehydratase;
2,3DH), methylations, transaminations, etc., to yield the
enormous variety of the 6DOH family (Salas and Méndez,
2005).
In recent years, the search for novel bioactive compounds
has followed a new strategy trying to overcome the problem
of re-discovery of already known compounds: the isolation of
the producing organisms in poorly characterized environments
such as marine sediments or in association with insects
(Poulsen et al., 2011). Leaf-cutting ants of the Tribe Attini
have attracted particular attention because they cultivate a
fungus in specialized chambers of their nests. The ants cut
leaves into small pieces and feed them to fungus, which
will serve as their source of food. To protect themselves
from fungal infections symbiotic microorganisms are located
on the integument of these ants. Although it was initially
assumed that they were Pseudonocardia spp. (Currie et al.,
1999), more recent evidence indicates that more than a single
symbiont exist in these ants, and microorganisms as Streptomyces
and Burkholderia are now thought to be involved in this
multitrophic interaction (Kost et al., 2007; Mueller et al.,
2008).
Different targeted screenings have been applied in the last
years for the discovery of novel bioactive natural products. These
include bioassay-guided approaches (Amagata et al., 2012; Wong
et al., 2012; Hassig et al., 2014; Shanbhag et al., 2015), search
of self-protection mechanisms of antibiotic producers (Thaker
et al., 2013), dereplication strategies of natural products using
high-resolution mass spectrometry (MS) (Chervin et al., 2017),
tandem MS for the search of particular structural features such
as glycosylated compounds (Kersten et al., 2013b), MS-based
proteomics of expressed enzymes such as polyketide synthases
(PKSs) and non-ribosomal peptide synthetases (NRPSs) involved
in natural product biosynthesis (Chen et al., 2016), and different
genetic approaches. The latter includes transcriptome analysis by
RNA sequencing (Jones et al., 2017), sequencing and mining of
microbial genomes or metagenomes in search of specific gene
homologs (Chang and Brady, 2013) or new BGCs (Kang, 2017),
and the use of polymerase chain reaction (PCR)-based screenings
of genes encoding enzymes implicated in the biosynthesis of
particular structural features of natural products such as NRPS
scaffolds (Bakal et al., 2015), PKS cores (Cao et al., 2010;
Kang and Brady, 2013) or deoxyhexose moieties (Wu et al.,
2013).
In this paper we searched for the presence of glycosylated
secondary metabolites in a collection of Streptomyces strains
isolated from leaf-cutting ants. By a combination of PCR-
based screening, MS dereplication and generation of mutants
we identified several already known compounds and two
novel macrolactams. In addition, by genome sequencing and
awakening approaches of BGCs we activate the expression of
two clusters for type II polyketides that are not expressed under
standard laboratory conditions leading to the identification of
two novel angucylines.
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MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
A collection of seventy one Streptomyces strains was used in
this work. For sporulation, strains were grown for 7 days at
30◦C on MA plates (Sánchez and Braña, 1996). For metabolite
production studies, spores were added to flasks containing
40 ml TSB medium and grown at 30◦C and 250 rpm.
After 24 h, this culture was used to inoculate 50 mL of
five different media to a final OD600nm = 0.2: R5A medium
(Fernández et al., 1998); SM medium (Zhang et al., 1992);
SM10 medium (per liter): 20.9 g MOPS, 11.5 g L-Proline, 23 g
glycerol, 0.5 g NaCl, 2.1 g K2HPO4, 0.28 g Na2SO4, 1 mL
MgSO4 0.2 M, 1 mL CaCl2 0.2 M and 5 mL trace elements
[composition per liter: 0.04 g ZnCl2, 0.2 g FeCl3.6H2O, 0.01 g
CuCl2.2H2O, 0.01 g MnCl2.4H2O, 0.01 g Na2B4O7.10H2O,
0.01 g (NH4)6Mo7O24.4H2O], pH 6.5; SM17 medium (per
liter): 2 g glucose, 40 g glycerol, 2 g soluble starch, 5 g
soybean flour, 5 g peptone, 5 g yeast extract, 5 g NaCl and
2 g CaCO3 in tap water; and SM19 medium (per liter): 40 g
tomato juice, 15 g oat flour and 2 g glucose. For intergeneric
conjugation, MS medium (Hobbs et al., 1989) was used.
Escherichia coli DH5α (Hanahan, 1983) was used as host for
cloning and E. coli ET12567/pUB307 for intergeneric conjugation
(ET12567/pUB307) (Kieser et al., 2000) and both were grown
in 2×TY medium supplemented, when required, with the
appropriate antibiotic.
Culture media were supplemented with antibiotics when
plasmid-bearing strains were used: apramycin (100 µg/mL for
E. coli, 25 µg/mL for Streptomyces), kanamycin (25 µg/mL),
tetracycline (10 µg/mL), chloramphenicol (25 µg/mL), and/or
nalidixic acid (50 µg/mL).
DNA Manipulation and Vectors
DNA manipulations were performed according to standard
procedures for E. coli (Sambrook et al., 1989) and Streptomyces
(Hanahan, 1983). Plasmids used in this work were pOJ260
(Bierman et al., 1992) for gene interruption and pEM4ATc,
pSETec (Cano-Prieto et al., 2015) and pOJ260P (Olano et al.,
2004) for gene expression under the control of ermE∗ promoter.
pEM4ATc was generated by cloning a BamHI-HindIII
fragment containing the apramycin resistance gene aac(3)IV
from pEFBA (Lozano et al., 2000) (ends were filled by
Klenow activity following manufacturer indications) into pEM4T
(Menendez et al., 2006) digested with EcoRV.
Plasmid Construction for Gene
Disruption
Probes 2,3DH and GS-DH were obtained by PCR amplification of
total DNA with degenerate oligonucleotide pairs PCR-D1a/PCR-
D1b (Trefzer et al., 2002) and AG5F/4,6DH2 (Hyun et al., 2000;
Ogasawara et al., 2004), respectively (Supplementary Table 12).
PCR conditions were: initial denaturation at 94◦C, 5 min;
35 cycles of 94◦C, 1 min, 60◦C, 1 min and 72◦C, 1 min
and a final extension cycle at 72◦C, 10 min. DreamTaq DNA
polymerase (Thermo Scientific) and 2.5% dimethyl sulfoxide
(DMSO) were used. Amplicons were verified by sequencing,
digested with EcoRI/HindIII and subcloned into pOJ260. The
resulting plasmids were introduced into Streptomyces strains by
intergeneric conjugation.
DNA Sequencing and Analysis
The Streptomyces sp. CS057, CS113, CS159 and CS227
chromosomes were sequenced at Department of Biochemistry,
University of Cambridge (Cambridge, United Kingdom) using
Illumina MiSeq Sequencing technology. De novo assemblies
were achieved using default parameters in Newbler assembler
software version 2.9. Annotation was performed using the
PGAAP pipeline1 (Angiuoli et al., 2008). Database searching and
sequence analysis were carried out with the bioinformatic tool
antiSMASH (Blin et al., 2017).
These Whole Genome Shotgun projects have been deposited
at DDBJ/ENA/GenBank under the accessions NEVF00000000
(Streptomyces sp. CS057), NEVC00000000 (Streptomyces
sp. CS113), NEVD00000000 (Streptomyces sp. CS159) and
NEVE01000000 (Streptomyces sp. CS227). The versions described
in this paper are version NEVF01000000, NEVC01000000,
NEVD01000000, and NEVE01000000, respectively.
Gene clusters for warkmycin and cervimycin have been
deposited at Minimum Information about a Biosynthetic Gene
Cluster (MIBiG) repository (Medema et al., 2015) under the
accessions BGC0001438 and BGC0001439, respectively.
Plasmid Construction for Cluster
Activation
For cluster activation in CS113, cmv22 was expressed under
the control of ermE∗p. A 0.96 kb fragment was amplified
with oligonucleotides 113-eSARP78.5b and 113-eSARP78.3b,
gel purified, digested with BamHI/EcoRI and cloned into
pSETec, pEM4ATc, and pOJ260P, leading to final plasmids
pSET113eSARP, pEM113eSARP, and pOJ113eSARP, respectively.
orf15 of CS159 was amplified with oligonucleotides
pErmE6RT15.5b and pErmE6RT15.3b. The resulting 0.79 kb
fragment was gel purified, digested with BamHI/EcoRI and
cloned into pSETec, pEM4ATc, and pOJ260P, leading to final
plasmids pSET159eRT15, pEM159eRT15, and pOJ159eRT15,
respectively.
Using genomic DNA of CS227, orf2 (0.92 kb) and orf37
(2.8 kb) were amplified with oligonucleotide pairs 227-
eSARP2.5/227-eSARP2.3 and 227-eLuxR37.5/227-eLuxR37.3,
respectively. Both amplicons were gel purified, digested
with BamHI/EcoRI and cloned into pSETec, pEM4ATc,
and pOJ260P, leading to final plasmids pSET227eSARP,
pEM227eSARP, pOJ227eSARP, pSET227eLuxR, pEM227eLuxR,
and pOJ227eLuxR.
wmc32 of CS057 was amplified with oligonucleotide
57-eReg.5b and 57-eReg.3b. A 0.84 kb fragment was gel purified,
digested with XbaI and cloned into pSETec, pEM4ATc, and
pOJ260P, leading to final plasmids pSET57eReg, pEM57eReg,
and pOJ57eReg, respectively. The correct orientation of wmc32
was confirmed by restriction enzyme digestion and sequencing.
1https://submit.ncbi.nlm.nih.gov/subs/wgs
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All amplifications were carried out with the high fidelity
polymerase Herculase II Fusion (Agilent Technologies) and PCR
conditions were: initial denaturation at 98◦C, 2 min.; 30 cycles of
98◦C, 30 s, 58◦C, 30 s and 72◦C, 30 s (3 min for orf37) and a final
extension at 72◦C, 3 min. The final plasmids were introduced
into their respective strains by intergeneric conjugation. All
oligonucleotides used are listed in Supplementary Table 12.
Analysis of Metabolites by UPLC and
Dereplication
Whole cultures (1 mL) of selected strains were extracted at
three different times (3, 5, and 7 days of culture) and with
three different organic solvents [ethyl acetate, ethyl acetate
containing formic acid (1%) or butanol] and analyzed by
reversed phase chromatography in an Acquity UPLC instrument
fitted with a BEHC18 column (1.7 µm, 2.1 mm × 100 mm,
Waters), with acetonitrile and MQ water + 0.1% TFA as
solvents. Samples were eluted with acetonitrile (10%) for 1 min,
followed by a linear gradient of acetonitrile (10–100%) over
7 min (flow rate of 0.5 mL/min; column temperature 35◦C).
For HPLC-MS analysis, an Alliance chromatographic system
coupled to a ZQ4000 mass spectrometer and a SunFire C18
column (3.5 µm, 2.1 mm × 150 mm, Waters) was used with the
above solvents. Elution was performed with an initial isocratic
hold with acetonitrile (10%) for 4 min followed by a linear
gradient of acetonitrile (10–88%) over 30 min (0.25 mL/min). MS
analyses were done by ESI in the positive mode (capillary voltage
3 kV, cone voltage 20 V). Detection and spectral characterization
of peaks were performed by photodiode array detection with
Empower software (Waters).
Isolation of Compounds from CS149 and
CS057
Products 11 and 12 were isolated from two-liter culture of
CS149 in R5A medium (40 mL × 50 mL, in 250 mL flasks).
After the mycelium was removed by centrifugation, supernatants
were filtered and then a pass-through cleanup strategy was used
on a C18 cartridge (10 g, Waters) to eliminate non-desirable
compounds. The sample was extracted with twice volume of ethyl
acetate, concentrated under vacuo, resuspended in 1.5 mL 50:50
DMSO:MeOH and subsequently subjected to semipreparative
HPLC using an Atlantis dC18 column (10µm, 10 mm× 150 mm,
Waters) and MQ water + 0.05% TFA/ACN (55:45) as a mobile
phase at 5 mL/min.
Products 22 and 24 were isolated from 5 mL × 400 mL (in
2 L flasks) cultures of CS057 in R5A medium whose supernatants
were first filtered, then concentrated on a C18 cartridge (10 g,
Waters), and subsequently fractioned on a 0.1% TFA–MeOH
gradient. Fractions containing desired compounds were dried
in vacuo, resuspended in 1mL of 50:50 DMSO:MeOH, and
processed on a preparative HPLC using a SunFire C18 column
(10 µm, 10 mm × 250 mm, Waters) and an isocratic mixture
60:40 MQ water:ACN at 5 mL/min.
The purity of the isolated peaks was determined by HPLC–
MS before structural elucidation. The isolated compounds were
then dried in vacuo, resuspended in 50:50 tert-butanol:water and
lyophilised. Yield and productivity of each compound was as
follows: 11, 1.1 mg (0.55 µg/mL); 12, 0.5 mg (0.25 µg/mL); 22,
2.1 mg (1.05 µg/mL); and 24, 5.8 mg (2.9 µg/mL).
Structural Elucidation of New
Compounds
The new compounds sipanmycin A (11), sipanmycin B (12),
warkmycin CS1 (22) and warkmycin CS2 (24) were analyzed
by LC-DAD-ESI-TOF to obtain their UV-vis (DAD) spectra and
determine their molecular formula based on the experimental
accurate masses and the corresponding isotopic distribution. The
structural elucidation of these compounds was carried out by
detailed analysis of 1D (1H) and 2D (COSY, TOCSY, NOESY,
HSQC and HMBC) NMR spectra further assisted by comparison
with the spectral data reported for incednine (Futamura et al.,
2008), silvalactam (Schultz et al., 2012), warkmycin and 4-
O-deacetyl-warkmycin (Helaly et al., 2013). Solvents used in
the NMR analyses were deuterated methanol (CD3OD) for
compounds 11 and 12, or deuterated chloroform (CDCl3) for
compounds 22 and 24. Relative configurations were determined
by coupling constants and NOEs analyses. The molecular model
of 11 was generated in Chem3D starting from the reported model
for incednine (Futamura et al., 2008).
LC-DAD-ESI-TOF and NMR Analyses
LC-DAD-ESI-TOF analyses were performed using an
Agilent 1200RR HPLC equipped with a SB-C8 column
(2.1 mm × 30 mm, Zorbax) coupled to a Bruker maXis
Spectrometer. Solvent A consisted of 10% acetonitrile and 90%
water with 1.3 mM trifluoroacetic acid (TFA) and ammonium
formate, and solvent B was 90% acetonitrile and 10% water with
1.3 mM TFA and ammonium formate. The gradient started at
10% B and went to 100% B in 6 min, kept at 100% B for 2 min
and returned to 10% B for 2 min to initialize the system. The
mass spectrometer was operated in positive ESI mode. The
instrumental parameters were: 4 kV capillary voltage, drying gas
flow of 11 L/min at 200◦C, nebulizer pressure at 2.8 bars. TFA-Na
cluster ions were used for mass calibration of the instrument
prior to sample injection. Pre-run calibration was by infusion
with the same TFA-Na calibrant.
NMR spectra were recorded at 24◦C on a Bruker AVANCE III-
500 MHz (500 and 125 MHz for 1H and 13C NMR, respectively)
equipped with a 1.7 mm TCI MicroCryoProbeTM, using the
residual solvent signal as internal reference. Structural features
were compared using the Dictionary of Natural Products (DPN)
NMR Features database created by Prof. John Blunt, as described
in Pérez-Victoria et al. (2016).
RESULTS
PCR Analysis of a Collection of
Actinomycetes Searching for Deoxy
Sugar Biosynthesis Genes
In the context of our study, a collection of seventy one
Streptomyces strains were screened for the presence of genes
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potentially involved in the biosynthesis of 6DOH. Total DNA
from these strains was extracted and purified, and the presence
of 6DOH biosynthesis genes determined by PCR analysis using
different primers. On one hand, two primers located one within
conserved regions in GSs (forward primer) and a second one
(reverse primer) located within conserved regions for NDP-D-
glycose-4,6-dehydratases (primers “GS-DH”). These two genes
are usually (but not exclusively) adjacent in the chromosome and
they are common to the biosynthesis of all 6DOH. The second
pair of primers corresponded to internal and conserved regions
for NDP-D-glucose-2,3-dehydratases, enzymes catalyzing the
2,3-dehydration step in the biosynthesis of 2,6-DOH (primers
“2,3DH”). PCR analysis of the strains showed that forty nine
strains gave positive amplicons with the “GS-DH” primers and
fifty-two strains with the “2,3DH” primers, with a total of
fifty-five strains being positive in at least one of the assays.
The presence of the expected DNA sequence was verified by
sequencing each amplicon.
Generation of Mutants by Gene
Disruption
The amplicons of the fifty five strains giving positive
amplification with any of the two pairs of oligo primers
were subcloned as EcoRI-HindIII fragments in pOJ260, an
E. coli vector unable of replication in Streptomyces. The resultant
constructs were introduced in the corresponding strains from
which they were originated by intergeneric conjugation E. coli-
Streptomyces and transconjugants selected for resistance to
apramycin (resistance marker in the vector). Because pOJ260
is a suicide vector in Streptomyces spp., these transconjugants
must be the consequence of an integration of the construct
in the chromosome by homologous recombination through
the insert in the vector. After several conjugation experiments,
transconjugants were obtained in ten of the fifty-five strains
tested. The lack of transconjugants in the remaining strains could
be due to low efficiency of transconjugation or recombination,
presence of DNA restriction systems, etc., but this was not further
studied. Four mutants were obtained using the corresponding
“GS-DH inserts” in the host strains CS65a, CS90a, CS149, and
CS227, and seven mutants using the “2,3DH inserts” in the host
strains CS57, CS92, CS113, CS123, CS147, CS149, and CS159.
In one case, strain CS149, mutants were obtained with both
“GS-DH” and “2,3DH” inserts.
UPLC Comparative Analyses of
Secondary Metabolites Production
In order to determine if inactivation of the selected 6DOH
biosynthesis genes gave rise to non-producing mutants and thus
to the identification of the produced compounds, the ten strains
and their corresponding mutants were grown on R5A liquid
medium. Cultures were extracted with three different solvent
systems (ethyl acetate, ethyl acetate plus 1% formic acid or
butanol) at 3, 5, and 7 days and the metabolic profiles analyzed
by UPLC. The different strains fall down in two different groups.
The first group included strains showing some differential peaks,
present in the wild type and absent in the mutant; this was the
case for six strains: CS065a, CS090a, CS92, CS123, CS147, and
CS149 (Figures 1A–F). The second group included strains not
showing differential peaks between the wild type and the mutant
strains in samples extracted with any of the solvents described
above or at any time tested; this was the case for four strains:
CS057, CS113, CS159, and CS227.
Extracts of the six strains of the first group and their
corresponding mutants were dereplicated by LC-UV-LRMS and
LC-HRMS against our in-house database (Pérez-Victoria et al.,
2016) and the Chapman & Hall Dictionary of Natural Products
(Buckingham, 2013) trying to determine if the differential
compounds were already known. In five out of the six
strains, compounds were identified in the differential peaks as:
chromomycins A3, Ap and A2 (peaks 1, 2 and 4 in strain
CS065a), benzanthrins A and B (both under the same peak
5 in strain CS090a), lobophorin A and B (peaks 6 and 8 in
strains CS092 and CS123) and vicenistatin (peak 10 in strain
CS147) (Figures 1A–E). In some cases, small minor peaks with
characteristic spectrum of the family were also detected and were
not further characterized (peak 3 from CS065a, 7 from CS092,
and 7 and 9 from CS123). All these identified compounds contain
6DOH attached to their respective aglyca and therefore it can be
assumed that the generated mutants were non-producer of the
corresponding compounds.
Identification of Two Novel
Macrolactams Produced by Strain CS149
The sixth strain (CS149) showing differential peaks that were not
identified by dereplication was characterized in more detail. Two
different mutants were obtained from this strain in which the
glucose synthase and 4,6-dehydratase genes (mutant int149-1)
or the 2,3-dehydratase gene were inactivated (mutant int149-2).
Comparative analysis of the UPLC profiles of wild type strain
CS149 and both mutants (Figure 1F) showed two differential
peaks, 11 and 12, absent in the mutant strain. From these
peaks, two compounds were isolated, purified and their structures
elucidated. These compounds, designated sipanmycin A (11) and
B (12), belong to a family of 24-membered macrolactams that
include incednine (13) (Futamura et al., 2008) and silvalactam
(14) (Schultz et al., 2012) (Figure 2).
The molecular formula of 11 was established as C46H71N3O8
based on the observed ion [M+Na]+ at 816.5143 (calcd. for
C46H71N3O8Na+ = 816.5133, 1m = 1.2 ppm) (Supplementary
Figure 1). Its UV (DAD) spectrum (Supplementary Figure 2)
shows a main maximum at 320 nm with a secondary maximum
(shoulder) at 360 nm, suggesting the presence of a polyene
moiety. Complete NMR spectral data including 1H, COSY,
TOCSY, NOESY, HSQC, and HMBC spectra were acquired to
determine the structure (Supplementary Figures 3–9). Although
the 1H spectrum showed broad signals, in the HSQC spectrum
fourteen sp2 methines could be identified which, according
to the COSY and TOCSY spectra, would belong to two
independent spin systems. This structural feature agrees with
the conjugated polyene motif compatible with the UV (DAD)
spectrum. On the other hand, two anomeric methine groups
from two different spin systems were likewise deduced from the
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FIGURE 1 | UPLC comparative analyses of the wild type strains and the different mutants. The numbers indicate differential peaks. Chromatograms of the wild type
strain are in black and those of the mutants in red. The wavelength at which each chromatogram was extracted is indicated in each panel.
1H, COSY, TOCSY and HSQC spectra, suggesting the presence
of two monosaccharide (aldose type) units. After searching
the DPN NMR Features database (Pérez-Victoria et al., 2016),
these structural features are found in incednine, a glycosylated
24-membered macrolactam natural product isolated from the
culture broth of Streptomyces sp. ML694-90F3 (Schultz et al.,
2012). Direct comparison of the NMR spectra of 11 with
the corresponding data reported for incednine confirmed the
structural similarity of both compounds. Thorough analysis
of the 2D NMR spectra assisted by comparisons with the
NMR data of incednine allowed stablishing the connectivity of
1 (Supplementary Figure 10). The 24-membered macrolactam
ring of 11 is identical to that of incednine differing just in
the side chain substituent at C-2, which for 11 is an isobutyl
chain instead of a methoxy group. Interestingly, the same
macrolactam ring aglycon is found in silvalactam (Schultz
et al., 2012), another closely related antibiotic which bears
just one monosaccharide. The pentopyranose (2-deoxy-2-amino-
β-D-xylopyranose) directly attached to the aglycon of 11 is
likewise almost identical to that found in incednine just
lacking the N-methylation. However, the second monosaccharide
unit (at the non-reducing end of the disaccharide moiety)
shows important differences. Compared to the corresponding
one in incednine it displays N-dimethylation rather than
monomethylation and it is not a deoxy sugar at C-3′′ carrying
at this position both a hydroxyl and a methyl group. The
relative configuration of the monosaccharides in 11 was
determined based on coupling constants and NOEs analysis
(Supplementary Figure 11). The absolute stereochemistry of
the chiral centers in 11 was assumed to be identical to
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FIGURE 2 | Chemical structures of members of the macrolactam family. The
two novel compounds, sipanmycins A and B, were isolated from peaks 11
and 12 (Figure 1F).
that reported for incednine (Futamura et al., 2008; Ohtani
et al., 2010) based on the key NOEs observed for 11 which
turned out to be identical to those reported for incednine.
Molecular modeling of 11 based on the reported models for
incednine and incednam (its aglycon) (Pérez-Victoria et al.,
2016), perfectly match these key NOEs and confirms that
the aglycon of 11 and incednam share the same absolute
stereochemistry (Supplementary Figure 12). In a similar fashion,
modeling also shows a perfect match with the key NOEs
involving the monosaccharides confirming the D-configuration
of both sugar units (Supplementary Figures 13, 14). The
monosaccharide glycosylating the macrolactam must share the
same biosynthetic pathway in incednine and 11 since they just
differ in an N-methylation. On the other hand, the non-reducing
monosaccharide in incednine is identical to D-forosamine
carrying just N-monomethylation instead of N-dimethylation. It
is reasonable to assume that the non-reducing monosaccharide
in 11 is being biosynthesized from D-glucose via a route
related to that of forosamine (Zhao et al., 2005; Hong et al.,
2008).
The molecular formula of 12 was established as C47H73N3O8
based on the observed ion [M+H]+ at 808.5475 (calcd. for
C47H74N3O8+ = 808.5470, 1m = 0.6 ppm) (Supplementary
Figure 15). This molecular formula contains one extra C atom
and two extra H atoms compared to 11. The UV (DAD)
spectrum (Supplementary Figure 16) was identical to that of
11. Likewise the complete NMR spectral set (Supplementary
Figures 17–22) showed just minor differences compared to
11. The structural relationship of 11 and 12 was obvious
and the difference was easily located, after analysis of the 2D
NMR spectra, in the side chain at C-2 being in this case a
2-methyl-1-butyl group (Supplementary Figures 23, 24). The
coincidence in chemical shifts of 11 and 12 (Supplementary
Tables 1, 2) indicates they share the same absolute configuration.
The absolute configuration of the extra chiral center in 2 (C-30)
could not be determined though.
Awakening of the Expression of Silent
Clusters
The four strains that did not show differential peaks by
comparison of the UPLC metabolic profiles (strains CS057,
CS113, CS159, and CS227) were further characterized in an
attempt to identify the BGC (if any) where the mutant
was generated and subsequently to identify the corresponding
compound. With this aim, we used two different strategies trying
to activate the expression of the corresponding silent clusters: a
nutritional and a genetic approach.
In the nutritional approach four different media (SM, SM10,
SM17, and SM19) differing in pH and in the carbon and
nitrogen sources were used. The strains were grown in these
media for several days and, after extraction with three different
solvent systems, the UPLC profiles were compared between
the wild type and the mutants. This kind of strategy has
proved to be successful in a wide range of microorganisms
(Bode et al., 2002). In the case of three strains (CS057, CS159,
and CS227) there were no significant differences suggesting
that none of the possible BGCs for secondary metabolites was
activated by changing the nutritional conditions. Consequently,
it was not possible to identify the compound coded by the
mutated cluster. However, UPLC profiles comparison between
strain CS113 and int113 mutant showed several differential
peaks when they were grown on SM19 medium (Figure 3A).
UPLC analysis and dereplication of the compounds present in
five peaks against our in-house database (Pérez-Victoria et al.,
2016), and the Chapman & Hall Dictionary of Natural Products
Compounds (Buckingham, 2013) revealed that, based on the
absorption spectrum and mass analysis, they contain compounds
compatible with members of the cervimycins family (Figure 3B),
a tetracycline-type compound with six 6DOHs attached. They
were identified as antibiotic HKI 10311129 (15, m/z = 1113.4765
[M+H]+), antibiotic A2121-1 (16, m/z = 1199.4794 [M+H]+),
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FIGURE 3 | Activation of the expression of cluster 23 in strain CS113. (A) UPLC comparative analysis of strain CS113 and mutant int113 grown on SM19 medium.
(B) Chemical structures of cervimycins (compounds from peaks 15 to 19). (C) UPLC comparative analysis of strain CS113 harboring vector pEM4AT or pEMSARP
both grown on R5A medium.
cervimycin D (17, m/z = 1213.4939 [M+H]+), cervimycin
C (18, m/z = 1227.5115 [M+H]+) and cervimycin A (19,
m/z = 1226.5152 [M+H]+) (Herold et al., 2004, 2005).
In the second approach we applied two different genetic
strategies that require the previous knowledge of the DNA
sequence and genetic organization of the targeted cluster.
For this approach, the genomes of the four strains were
sequenced and searched for the presence of putative BGCs using
the bioinformatic tool “antibiotics and Secondary Metabolite
Analysis Shell” (antiSMASH v.4) (Blin et al., 2017). All strains
showed the presence of a large number of BCGs (between 20 and
33) with only one glycosylated BGC in strains CS113 (cluster 23,
Supplementary Table 3), CS159 (cluster 26, Supplementary
Table 4) and CS227 (cluster 21, Supplementary Table 5), and
two glycosylated BCGs in strain CS057 (clusters 14 and 19,
Supplementary Table 6). Sequence analysis allowed us to confirm
that the mutants in strains CS113, CS159, and CS227 were
effectively generated in the corresponding glycosylated BGC and,
in the case of CS057, at cluster 14. The genetic organization
of these four clusters is shown in Figure 4. All four clusters
seemed to contain at least one putative pathway-specific positive
regulatory gene for the putative control of secondary metabolite
biosynthesis. In order to attempt the activation of the expression
of these clusters we used two approaches: (i) inserting a strong
and constitutive promotor (ermE∗p) in the chromosome to
control the expression of the putative regulatory gene or (ii)
ectopic expression of the regulatory gene under the control
of ermE∗p in the wild type strain either using a replicative
(pEM4AT) or an integrative (pSET152e) vector.
Cluster 23 in Strain CS113
This 40 kb BGC would code for a type II polyketide that
could contain at least five 6DOH based on the presence of
five glycosyltransferase genes (Figure 4A and Supplementary
Table 7). AntiSMASH analysis revealed that 41 and 39% of
the genes belonging to this cluster show similarity with genes
of the already described polyketomycin (Daum et al., 2009)
and dutomycin (Sun et al., 2016) clusters, respectively, the
main difference being the presence of two genes putatively
involved in the biosynthesis of an “asparagine unit” in cluster
23 (cvm4 and cvm31 in Figure 4A). The cluster contains a
putative positive regulatory gene (cvm22, Supplementary Table 7)
belonging to the SARP family. Upon expression of this gene in
the replicative and the integrative plasmids under the control of
the ermE∗p or by inserting this promotor upfront of the cvm22
gene, production of five cervimycins (15–19) was observed,
being absent in the wild type strain only containing the vector
(Figure 3C). Therefore, we can conclude that cluster 23 is not
expressed in the wild type strain under our standard cultivation
conditions (i.e., R5A medium) but its awakening is possible by
manipulating the expression of the regulatory gene cvm22. To
our knowledge, the cvm cluster involved in the biosynthesis
of cervimycins in Streptomyces tendae HKI-179 has not been
previously described, being only the nucleotide sequence of
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FIGURE 4 | Genetic organization of several clusters identified in this study. (A) Cluster 23 from CS113 (cvm). (B) Cluster 25 from CS159. (C) Cluster 21 from CS227.
(D) Cluster 14 from CS057 (wmc). Generic functions for the gene products are indicated using colored code.
cerJ (ketosynthase) available at GenBank (accession number
JN001183) (Bretschneider et al., 2011).
Cluster 26 in Strain CS159
This cluster also could code for a compound with at
least three 6DOH attached to the aglycon since there are
three glycosyltransferase genes (Figure 4B and Supplementary
Table 8). It could be a type II polyketide based on the
presence of genes coding for an acyl carrier protein (orf3), a
ketoacyl reductase (orf4) and two cyclases (orf2 and orf5), but
genes encoding for beta-ketoacyl synthases (KS) are missing.
Hypothetically, the lack of these genes could be overcome by
the presence of two orphan KSs in the vicinity of cluster 26, in
particular at cluster 24 (Supplementary Table 4). By searching
in databases we found the closest similar cluster (44% identity)
being that for the biosynthesis of lomaiviticin from marine
actinomycetes Salinispora pacifica DPJ-0019 (Woo et al., 2012)
and Salinispora tropica CNB-440 (Kersten et al., 2013a). Among
the 61.5 kb of cluster 26 there are six structural genes (and
other three with unassigned function) without any ortholog
at the lomaiviticin gene cluster that let us hypothesize the
compound coded by this cluster may be related but different
from lomaiviticin. Interestingly, most of the genes contained in
cluster 26 have an ortholog in the same region of the genome of
Streptomyces sp. NRRL WC-3753 thus indicating that this cluster
may be present in both strains (Supplementary Table 8).
Based on the absorption spectrum of lovaimiticin, we searched
by UPLC for the presence of compounds with a similar spectrum
but we were unsuccessful. The cluster contains a potential
positive regulator of the OmpR family (orf15), a type of regulator
that had been proven as an activator of the production of several
secondary metabolites such as nikkomycin (Liu et al., 2005)
and jadomycin B (Wang et al., 2009). Attempts to activate the
expression of this gene and the subsequent production of the
targeted compound were also unsuccessful. As a conclusion, the
compound coded by this cluster remains unknown.
Cluster 21 in Strain CS227
This cluster is one of the longest BGC described until now
in Streptomyces (195 kb) and it might be responsible for the
production of a large type I polyketide with at least one sugar
attached to the aglycon as suggested by the presence of one
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glycosyltransferase gene (Figure 4C and Supplementary Table 9).
Searching in databases showed that 68% of the genes in this
cluster presented similarity with genes from the 51-membered
macrolide stambomycin BCG (Laureti et al., 2011). In fact, all
the PKSs encoded by cluster 21 of CS227 (except Orf20 and
Orf21) and those of the stambomycin cluster of Streptomyces
ambofaciens ATCC23877 are very similar both in amino acid
sequence (percentage of identity ranging between 55 and 80;
Supplementary Table 9) and domain architecture (they share
the same predicted modules and domains) The main differences
concerning PKSs of both clusters relay in PKS Orf20 that shares
the first two modules with SAMR466 but has four additional
modules and in PKS Orf21, composed by four modules,
that has not an ortholog in the stambomycin biosynthesis
cluster. Furthermore, acyltransferase domain analysis using
antiSMASH and PRISM software (Skinnider et al., 2016)
predicts that 23 × malonyl-CoA, 9 × methylmalonyl-CoA
and one ethylmalonyl-CoA units might participate in the
biosynthesis of the final compound in CS227, whilst in
stambomycin biosynthesis the PKSs introduce 16 × malonyl-
CoA, 8 × methylmalonyl-CoA and one unusual alkylmalonyl-
CoA unit (Laureti et al., 2011; Ray et al., 2016). In addition, the
proposed functions for the enzymes involved in the biosynthesis
of the sugar attached to the polyketide deduced from cluster 21 of
CS227 indicates that it might be a 3-amino-2,6-DOH, in contrast
to the 3-amino-6-DOH β-mycaminose of stambomycins.
Stambomycins are not produced by S. ambofaciens under
normal laboratory growth conditions. However, the constitutive
expression of a regulatory gene of the LuxR family located
within the cluster triggered the expression of the biosynthetic
genes leading to the identification of four stambomycins (Laureti
et al., 2011). In our cluster, we found several potential positive
regulatory genes belonging to the SARP (orf2 and orf8) and
LuxR family (orf37) (Figure 4C). Giving the similarity between
both clusters we attempted to activate cluster 21 by independent
expression of both types of transcriptional activator genes
(orf2 and orf37) in a replicative or an integrative vector and
also by inserting the ermE∗p in the chromosome upfront each
of these genes. In all the cases, no differential peaks were found.
Therefore, we could not identify the compound encoded by the
analyzed cluster.
Cluster 14 in Strain CS057
This 38 kb BGC could code for a type II polyketide (Figure 4D
and Supplementary Table 10). AntiSMASH analysis showed 68%
of genes in this cluster presenting similarity with genes involved
in the biosynthesis of the angucycline landomycin. There are
four glycosyltransferase genes at this cluster that suggested the
presence of a minimum of four 6DOH in the final compound.
Cluster 14 also contains a possible transcriptional activator gene
of the OmpR-family (wmc32). By using both genetic strategies
mentioned above, we found five differential peaks (20–24)
between the experimental strains and the corresponding controls,
all of them sharing the same absorption spectrum (Figure 5A).
Dereplication of the compounds in these peaks against our
in-house database (Pérez-Victoria et al., 2016) and the Chapman
& Hall Dictionary of Natural Products (Buckingham, 2013)
showed that they could be related to the glycosylated angucycline
warkmycin (Helaly et al., 2013). To confirm the novelty of these
compounds, two of them (22, m/z = 1025.4341 [M+NH4]+; and
24, m/z= 1049.4104 [M+H]+) were purified and their structures
elucidated and named warkmycin CS1 and CS2, respectively
(Figure 5B).
Compound 22 showed a UV (DAD) spectrum
(Supplementary Figure 25) with a maximum at 220 nm
identical to that reported for warkmycin. Its molecular
FIGURE 5 | Activation of the expression of cluster 14 in strain CS057. (A) UPLC comparative analysis of strain CS057 harboring vector pSET152, mutant int057 and
strain CS057 harboring pSET57reg (expressing wmc32) grown on R5A medium. (B) Chemical structures of warkmycins CS1 (22) and CS2 (24).
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formula was established as C48H65NO22 based on the
observed ion [M+NH4]+ at 1025.4341 (calcd. for
C48H69N2O22+ = 1025.4336, 1m = 0.5 ppm) (Supplementary
Figures 26, 27). The molecular formula matches that of 4-
O-deacetyl-warkmycin. However, this known warkmycin
could not explain the fragments observed in-source in the
HRMS experiment. Thus, a complete set of NMR spectra
including 1H, COSY, TOCSY, NOESY, HSQC and HMBC spectra
(Supplementary Figures 29–34) was acquired to ensure the
novelty of 22 and determine its structure. The analysis of the
NMR data confirmed 22 as a novel warkmycin displaying for
most signals almost identical chemical shift compared with
4-O-deacetyl-warkmycin. The main differences were observed
for the resonances of sugar rings A and D. Such difference
turned out to be a consequence of the different position of the
carbamoyl functional group which is located at position 4 of the
sugar ring D in 22 while in 4-O-deacetyl-warkmycin is placed
at position 4 of the sugar ring A. The key HMBC observed
between the proton at position C-4D and the carbonyl carbon
of the carbamoyl functionality unequivocally distinguishes 22
from its regioisomer (4-O-deacetyl-warkmycin) (Supplementary
Figure 35). The mentioned in-source fragments observed in its
HRMS spectrum likewise unequivocally located the carbamoyl
functionality at sugar ring D (Supplementary Figure 28).
The UV spectrum of compound 24 (Supplementary Figure 36)
was identical to 22. Its molecular formula was established
as C50H67NO23 based on the observed ion [M+NH4]+
at 1067.4450 (calcd. for C50H71N2O23+ = 1067.4442,
1m = 0.9 ppm) (Supplementary Figure 37). The difference
in its molecular formula compared with 22 immediately
indicated that 24 bears an extra acetyl group. Once again 24
shares the same molecular formula as warkmycin but the analysis
of the NMR spectral data (Supplementary Figures 38–45) and
the in-source fragmentation observed in its HRMS spectrum
unequivocally located the position of the carbamoyl in the
same place found in 22. Thus 24 is a regioisomer of warkmycin
and is identical to 22 carrying an extra acyl group at C-4. The
effect of the extra acylation is reflected in the corresponding
shifting in resonance frequency for the nearby positions to C-4
(Supplementary Table 11).
The absolute stereochemistry of 22 and 24 is identical to
that reported for the known warkmycins based on chemical
shift comparisons and the observation of the same coupling
constants pattern and key NOEs as those reported for warkmycin
(Supplementary Figures 46, 47).
DISCUSSION
The search for novel bioactive natural products is a challenge
for researchers in the field based on the need to combat
emergent infectious diseases and resistant pathogens in the
field of antibiotics or to find better chemotherapeutic drugs
in the field of antitumor drugs (Newman and Cragg, 2016;
Zhang et al., 2017a). Through classical screening programs
a large number of bioactive compounds have been isolated
and many of them arrived to clinical use (Katz and Baltz,
2016). However, these screenings have a low hit rate but
a high rediscovery rate being necessary to isolate a large
number of strains from different origins and to test many
extracts in order to identify a novel compound (Zhang
et al., 2017a). It is therefore an expensive, low productive
and time-consuming work. Consequently, novel approaches
must be developed to improve the chances of getting novel
bioactive natural products. The continuously growing available
information on the sequencing of genomes of microorganisms,
and in particular those for actinomycetes, is revealing the
large potential of these microorganisms to synthesize a
enormous variety of compounds, many of which are not
produced under standard laboratory cultivation conditions.
Targeted screening in combination with genome mining can
increase the chance of discovering novel compounds, as it
is shown in this work were we have focused our efforts to
identify novel glycosylated natural products. However, in many
cases not even a combination of screening approaches can
deal with the fact that some BGCs are silenced under the
laboratory conditions used. Access to this potential reservoir
of bioactive molecules can be only achieved at present using
recombinant DNA technology in combination with genome
sequencing (Rutledge and Challis, 2015; Zarins-Tutt et al.,
2016; Ren et al., 2017). In this work, we have used such an
approach to target BGCs coding for compounds containing
6DOH in their structures. The reason to select these type
of compounds resides in the fact that many therapeutically
important antibiotics, antifungals, antiparasitics and anticancer
drugs contain 6DOH attached to the aglycone core (Salas and
Méndez, 2007).
In order to search for glycosylated BGCs in the genome
of seventy-one streptomycete strains we choose several 6DOH
genes as targets. On one hand, two genes very well conserved
whose products catalyze the two earliest and common steps in
the biosynthesis of 6DOH: a GS and a DH, thus conducting
to the biosynthesis of 6DOH. In most of the BGCs so far
characterized they are linked together in the chromosome and
usually they are forming part of the BGC with a few exceptions,
the most representative ones include genes involved in the
biosynthesis of L-rhamnose which are not located inside the
corresponding BGC (Madduri et al., 2001; Gullon et al., 2006;
Ramos et al., 2008). The use of these two genes as probes is a
quite efficient strategy since, based on the information emerging
from the sequence of the genomes of many streptomycetes,
they do not contain a large number of glycosylated BGCs
per organism: on average between none and one glycosylated
cluster can be found in each strain. The second targeted
gene, coding for a NDP-D-glucose-2,3-dehydratase, participates
in the biosynthesis of 2,6-DOH and therefore is a more
selective probe. In our study, 77% of the strains tested gave
positive results against at least one of the probes, 69 and 73%
giving positive against the “GS-DH” and the “2,3DH” probes,
respectively.
Insertional inactivation of a gene cluster by homologous
recombination is a usual genetic tool to prove the involvement
of a BGC in the production of a given compound (Olano
et al., 2011). In our study, ten mutants were obtained affecting
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different clusters. Comparative analyses between the UPLC
profiles of the wild type and the corresponding mutant was
sufficient to detect changes in the profile of six strains and the
identification by dereplication of the potential compounds coded
by the targeted BGC in each mutant. This was a clear proof of
concept: the strategy allows achieving the proposed objective,
the identification of a BGC for a glycosylated compound. Some
of these compounds were not further characterized since they
corresponded to already known compounds. However, in the
case of strain CS149 two novel macrolactams, sipanmycin A
(11) and B (12), were isolated and purified. They are related
to incednine and silvalactam, but mainly differing in the sugar
pattern of the compounds. Incednine has been shown as a potent
modulator of the anti-apoptotic function of Bcl-xL, thus having
potential implications in cancer chemotherapy (Futamura et al.,
2008).
UPLC profiles comparison was not sufficient to identify
the produced compound by some of the clusters since no
differential peaks were observed even after several incubation
days and using different extraction systems. This might be
due to the fact that some BGCs are not expressed under
normal laboratory conditions and it is necessary to force
the expression of the corresponding cluster. Using nutritional
and genetic approaches (Bode et al., 2002; Rutledge and
Challis, 2015), we have been successful in activating the
expression of two “silent” BGCs in two different strains
out of four strains tested. In strain CS113, detection of
the production of members of the cervimycin family of
antibiotics was achieved by changing the composition of
the growth medium or by manipulating the expression of
a positive regulator of the SARP family. In strain CS057
production of five members of the warkmycin family of
antibiotic and cytotoxic compounds, two of them novel
members, arose as a consequence of the manipulation of the
expression of a transcriptional activator gene of the OmpR-
family.
Biosynthesis of different compounds by actinomycetes may
confer the producer strains with competitive advantages in the
environment where they live. In the case of the strains in
this study, isolated from the integuments of ants, it could be
also an evolutionary advantage for the ants to be protected
from pathogen microorganisms that could be a threat for their
survival. Ants have been shown to be infected by different
fungal pathogens (Yek et al., 2013) and different reports, in
addition to the work we described here, pointed out to the
identification of bioactive natural products from actinomycetes
living in symbiosis with the ants (Seipke et al., 2012; Van Arnam
et al., 2015, 2016).
CONCLUSION
Sequencing of the genomes of actinomycetes has revealed a
large potential for the biosynthesis of bioactive natural products
in these organisms. Target-directed search for clusters coding
for glycosylated bioactive compounds using a combination of
different approaches has been proven as a good strategy in the
search for novel compounds. Once the clusters are identified
different approaches can be applied in order to activate the
expression of “silent” or “low expressed” BGCs thus conducting
to the identification and isolation of novel bioactive compounds.
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